People: Trinity Biotech PLC (TRIB.O)

TRIB.O on Nasdaq

16.87USD
21 Nov 2014
Price Change (% chg)

$-0.17 (-1.00%)
Prev Close
$17.04
Open
$17.00
Day's High
$17.25
Day's Low
$16.86
Volume
71,277
Avg. Vol
132,258
52-wk High
$28.06
52-wk Low
$14.00

Search Stocks

Summary

Name Age Since Current Position

Ronan O'Caoimh

57 2011 Executive Chairman of the Board

Kevin Tansley

42 2007 Chief Financial Officer, Secretary

Rory Nealon

45 2007 Chief Operating Officer, Executive Director

James Walsh

54 2010 Chief Scientific Officer, Executive Director

Clinton Severson

66 2008 Non-Executive Director

Denis Burger

69 2010 Senior Non-Executive Independent Director

Peter Coyne

53 2001 Non-Executive Independent Director

James Merselis

2009 Non-Executive Independent Director

Biographies

Name Description

Ronan O'Caoimh

Ronan O'Caoimh is the Chairman and Chief Executive Officer of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Ronan co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. In November 2007, it was decided to separate the role of Chief Executive Officer and Chairman and Mr O’Caoimh assumed the role of Executive Chairman. In October 2008, following the resignation of the Chief Executive Officer, Mr O’Caoimh resumed the role of Chief Executive Officer and Chairman. Prior to joining Trinity Biotech, Mr O’Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O’Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr O’Caoimh holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. On March 30, 2011, the service agreement with Ronan O’Caoimh as Chief Executive Officer was terminated and replaced by an agreement with Darnick Company.

Kevin Tansley

Kevin Tansley is a Chief Financial Officer of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Kevin joined Trinity Biotech in March 2003 and was appointed Chief Financial Officer and Secretary to the Board of Directors in November 2007. Mr. Tansley trained as a chartered accountant in the Corporate Financial Services practice of Arthur Andersen & Co. Prior to joining Trinity Biotech in 2003, Mr. Tansley held a number of financial positions in the Irish electricity utility ESB. Mr. Tansley holds a Masters of Accounting from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

Rory Nealon

Rory Nealon is a Chief Operations Officer of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Rory joined Trinity Biotech as Chief Financial Officer and Company Secretary in January 2003. He was appointed Chief Operations Officer in November 2007. Prior to joining Trinity Biotech, he was Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland. Prior to joining Conduit he was an Associate Director in AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group. Mr Nealon holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK.

James Walsh

James Walsh, PhD. is the Executive Director of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Jim initially joined Trinity Biotech in October 1995 as Chief Operations Officer. Dr. Walsh resigned from the role of Chief Operations Officer in 2007 to become a Non Executive Director of the Company. In October, 2010 Dr. Walsh rejoined the company as Chief Scientific Officer. Prior to joining Trinity Biotech, Dr. Walsh was Managing Director of Cambridge Diagnostics Ireland Limited (CDIL). He was employed with CDIL since 1987. Before joining CDIL he worked with Fleming GmbH as Research & Development Manager. Dr. Walsh holds a PhD in Chemistry from University College Galway.

Clinton Severson

Clinton Severson is a Non-executive director of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Clinton joined the board of Trinity Biotech in November 2008 as a non-executive director. Mr. Severson is currently Chairman, President and CEO of Abaxis Inc., a NASDAQ traded diagnostics company based in Union City, California. From February 1989 to May 1996, Mr. Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company and to date he has accumulated over 30 years experience in the medical diagnostics industry.

Denis Burger

Denis R. Burger, PhD. is a Non-executive director of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Deniis co-founded Trinity Biotech in June 1992 and was Chairman from June 1992 to May 1995. He is currently Chairman of AMES technology, a private medical device company, and is also non-executive director of Lorus Therapeutics, Inc, a cancer therapeutics, TSX listed company. Until March 2007, Dr. Burger was the Chairman and Chief Executive Officer of AVI Biopharma Inc, a NASDAQ listed biotechnology company. He was also a co-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr. Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his degree in Bacteriology and Immunology from the University of California in Berkeley in 1965 and his Master of Science and PhD in 1969 in Microbiology and Immunology from the University of Arizona.

Peter Coyne

Peter Coyne is a Non-executive director of TRINITY BIOTECH PUBLIC LIMITED COMPANY. Peter joined the board of Trinity Biotech in November 2001 as a non-executive director. Mr. Coyne trained as a chartered accountant in the Corporate Financial Services practice of Arthur Andersen & Co. Mr. Coyne was previously a director of AIB Corporate Finance and has extensive experience of advising boards on mergers and acquisitions and corporate strategy. Mr. Coyne is a partner of VISION Consulting, an international consulting firm delivering breakthrough solutions in customer service and leadership development. Mr. Coyne is a non-executive director of Ark Life Assurance Company Limited. Mr. Coyne holds a bachelor of engineering degree from University College Dublin, is a fellow of the Institute of Chartered Accountants in Ireland and is a CEDR Accredited Mediator.

James Merselis

James D. Merselis is a Non-executive director of TRINITY BIOTECH PUBLIC LIMITED COMPANY. James joined the board of Trinity Biotech in February 2009 as a non-executive director. He is currently CEO of Biosensia Ltd; a point-of-care diagnostics company located in Dublin, Ireland and is on the boards of Abram Scientific Inc. located in Mountain View, CA, and Cardiac Designs Inc. located in Austin, TX. Mr. Merselis has more than thirty-seven years experience in healthcare, with the first twenty-two years at Boehringer Mannheim Diagnostics (now Roche Diagnostics). Mr. Merselis has led a number of healthcare diagnostic start-ups. From 2002 to 2007, he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of Warfarin or Coumadin. During this time he successfully took the company public (NASDAQ:HEM) followed two years later by its acquisition by Alere (NYSE: ALR). His leadership at other start-ups has included: Nexus Dx (now Samsung), Alverix, Inc. (now Becton Dickenson), and Micronics, Inc. (now SONY).

Basic Compensation

Name Fiscal Year Total

Ronan O'Caoimh

877,000

Kevin Tansley

353,000

Rory Nealon

544,000

James Walsh

478,000

Clinton Severson

--

Denis Burger

--

Peter Coyne

--

James Merselis

--
As Of 30 Dec 2013

Options Compensation

Search Stocks